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Summary 
Upon cellular DNA damage, the p53 tumor suppressor 
protein transmits a signal to genes that control the 
cell cycle and apoptosis. One function of p53 that is 
important for its role in thi s pathway is its ability to 
function as a sequence-specific transcriptional activa- 
tor. We demonstrate here that short single DNA 
strands can markedly stimulate the ability of human 
and murine p53 proteins to bind specifically to a I)53 
response element in supercoiled DNA. We also show 
that single-stranded DNA does not stimulate binding 
by a truncated p53 that lacks the C-terminal domain. 
Finally, we establish that a poptide spanning the p53 
C-terminus has the ability in trans to stimulate se- 
quence-specific DNA binding by p53 dramatically. 
These data taken together suggest a model in which 
the p53 C-terminus can recognize DNA structures re- 
suiting from damage-induced lesions, and this interac- 
tion can be propagated to regulate positively p53 se- 
quence-specific DNA binding. 
Introduction 
Signals emanating from damaged DNA cause the p53 re- 
sponse pathway to be activated (reviewed by Donehower 
and Bradley, 1993). Disruption of this pathway, which is 
clearly of central importance for maintaining the integrity 
of the genome of higher eukaryotes, correlates with onco- 
genesis. It is well established that p53 recognizes se- 
quences conforming to the p53 consensus-binding site 
(reviewed by Vogelstein and Kinzler, 1992). The impor- 
tance of the DNA binding property of p53 is underscored 
by the fact that the vast majority of mutations in p53 genes 
cloned from tumors are located within the centrally located 
sequence-specific p53 DNA-binding domain (see Hollstein 
et al., 1994). It is therefore important o understand how 
DNA binding by p53 is regulated. 
The overall arrangement of p53 functional domains has 
been defined (reviewed by Prives et al., 1994). Like many 
other transcriptional activators, p53 contains an activation 
region, a specific DNA-binding domain, and an oligomer- 
ization domain. The structures of the DNA-binding (Cho 
et al., 1994) and oligomerization domains (Clore et al., 
1994; Lee et al., 1994; Jeffrey et al., 1995) have been 
solved. The DNA-binding domain alone can bind well and 
highly specifically to DNA (Pavletich et al., 1993; Bargo- 
netti et al., 1993; Wang et al., 1993). Yet, as part of the 
full-length protein, it is subject to regulation by sequences 
outside of it (Hupp et al., 1992; Halazonetis et al., 1993; 
Pietenpol et al., 1994; Wang and Prives, submitted). Cells 
subjected to DNA-damaging agents accumulate p53, and, 
depending on factors such as cell environment or geno- 
type, either undergo arrest primarily in G1 or apoptosis 
(reviewed by White, 1994). Indeed, a number of genes 
have been identified that are clearly activated in cells by 
p53 after DNA damage ensues. These include GADD45 
(Kastan et al., 1992), MDM2 (Perry et al., 1993; Chert et 
al., 1994), WAFllp211CIP1 (EI-Deiry et al., 1993; Dulid et 
al., 1994), and cyclin G (Okamoto and Beach, 1994). Each 
of these genes can be rationalized to be functional in a 
DNA damage-initiated pathway, and all have been shown 
to contain p53-binding sites. 
Less well understood in the p53 pathway is how the 
signal is relayed from damaged DNA to p53. One feature 
of damaged DNA that appears essential for accumulation 
of p53 is the appearance of strand breaks (Lu and Lane, 
1993; Nelson and Kastan, 1994). But it is not unlikely that 
more than one determinant can transmit he signal. We 
have considered the possibility that one recipient of a sig- 
nal from damaged DNA is p53 itself. Our rationale is based 
on several studies showing that the C-terminus of p53 can 
recognize features such as short single strands and DNA 
ends that are likely to be .present in irradiated cells. In 
particular, p53 has a potent DNA strand-reannealing activ- 
ity (Oberosler et al., 1993; Bakalkin et al., 1994), and this 
activity is a function exclusively of the C-terminus since 
this region alone is sufficient to reanneal complementary 
single strands (Brain and Jenkins, 1994; Prives et al., 
1994; Wu et al., 1995; Bakalkin et al., 1995). The C-ter- 
minus of p53 (spanning residues 311-393) contains at 
least two structural determinants, the tetramerization re- 
gion (amino acids 319-360) and an adjacent.region (amino 
acids 363-393) that is rich is basic residues. This region 
is also necessary for the ability of p53 to bind and reanneal 
complementary DNA single strands (Prives et al., 1994). 
We have considered the po§sibility that the C-terminus 
may interact with single-stranded DNA and that this inter- 
action may activate the p53 DNA-binding domain and 
therefore the transcriptional activity of p53. 
Results 
Short Single Strands of DNA Stimulate p53 
Binding to Its Cognate Site 
We reasoned that, if found, a stimulatory effect of short 
DNA would be most evident (and perhaps more physiologi- 
cally relevant) if p53 were bound to a site in closed circular 
DNA. To test this, we examined the effects of long (2.6 
kb) native or heat-denatured (mostly single-stranded) or 
short (40 nt) single-stranded or double-stranded oligonu- 
cleotides on purified human p53 binding to a supercoiled 
plasmid into which the GADD~45 p53-binding site was 
cloned (Figure 1). p53 binding alone was adjusted (after 
preliminary binding curves were established) such that 
protection of the GADD45 site was relatively weak (Figure 
1A, lane 2). We observed that long denatured DNA not only 
failed to stimulate binding but actually completely inhibited 
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Figure 1. Short Single-Stranded DNA Frag- 
ments Stimulate Sequence-Specific Binding 
by Wild-Type Human p53 
(A) Human p53 protein (hp53) (1 I~g) was bound 
to a wild-type GADD45 site-containing plasmid 
(100 ng), and primer extension footprinting was 
carried out as described in Experimental Pro- 
cedures. Binding reaction mixtures contained 
either no protein (lane 1) or 1 p.g of p53 (lanes 
2-10) and either no DNA fragments (lanes 1 
and 2) or 400 ng and 800 ng, respectively, of
long single-stranded DNA (lanes 3 and 4), long 
double-stranded D NA (lanes 5 and 6), short sin- 
gle-stranded DNA (lanes 7 and 8) or short dou- 
ble-stranded DNA (lanes 9 and 10). 
(B) Human p53 protein (hp53) (l~g) was bound 
to a GADD45 site-containing plasmid (100 ng), 
and primer extension footprinting was per- 
formed as in (A). Binding reactions contained 
either no protein (lane 1) or 1 p.g of p53 (lanes 
2-7) and either no DNA fragments (lanes t and 
2) or 1000 ng of a 19-mer (lane 3), a 21-mer 
(lane 4), or a 30-mer (lane 5) or 2200 ng of a 
66-mer (lane 6) or a 92-mer (lane 7). The very 
dark band in the lower egion of the GADD45- 
protected site is a primer artifact. 
any protection of this region, while long or short duplex 
DNA stands were without significant effect. By contrast, 
in the presence of a short single-stranded oligonucleotide 
i.e., a 40-mer, p53 binding to the GADD45 site was mark- 
edly and consistently increased such that the two 10 nt 
half-sites that make up the p53-binding site were each 
very well protected. The quantity of short single-stranded 
DNA that was required to produce the stimulatory effect 
was in the stoichiometric rather than the catalytic range 
(1-4 mol of single-stranded DNA per mole of p53). To 
obtain further information on the size of single-stranded 
DNA molecules that could stimulate p53 binding a range 
of oligonucleotides (containing 19, 21,30, 66, or 92 nucleo- 
tides) were then tested (Figure 1 B). The results were strik- 
ing: taken together with the data shown in Figure 1A, oligo- 
mers up to 40 bases in length were stimulatory. However, 
those containing 66 or 92 nucleotides were actually inhibi- 
tory to binding. This inhibition was observed when these 
longer oligomers were tested at either mass or molar 
equivalence to the 30-mer. Thus, there is a sharp transition 
between the length of a single-stranded DNA molecule 
that will activate p53 DNA binding and one, merely 25 
bases longer, that not only fails to stimulate but actually 
inhibits. The sequences of the single-stranded oligonu- 
cleotides were most likely unimportant because there was 
no obvious relationship between the various oligonucleo- 
tides that stimulated or inhibited. 
We tested whether purified murine p53 binding to su- 
percoiled DNA could also be stimulated by short oligonu- 
cleotides (Figure 2). Additionally, since the C-terminus of 
p53 contains the region that binds to and anneals single- 
stranded DNA, we asked whether (murine) p53 that lacks 
the C-terminus but retains the ability to bind to a cognate 
site can be stimulated by single-stranded DNA. Baculovi- 
ruses encoding either murine full-length p53 or p53 con- 
taining amino acids 1-320 (Wang et al., 1993) were used 
as a source of immunopurified p53 proteins. Note that 
the murine p53 produced a substantially different footprint 
from human p53: murine p53 protected sequences within 
(solid line in Figure 2) and also adjacent o (dotted line in 
Figure 2) the GADD45 site. While the short oligonucleotide 
stimulated full-length murine p53 protection of the GADD45 
site in superooiled DNA, there was no increase in protec- 
tion of this site when p53(1-320) was used. Thus, the p53 
response to short single strands is conserved between 
human and murine species. Perhaps of greater signifi- 
cance, these data suggest that the p53 C-terminus is nec- 
essary for stimulation by short single strands of DNA. 
The p53 C-Terminus Stimulates ~equence-Specific 
DNA Binding by the p53 DNA-Binding Domain 
The experiments described above suggested that the p53 
C-terminus, through its interactions with short single 
strands, may be capable of increasing the~affinity of the 
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Figure 2. Binding by Full-Length M urine p53 but Not C-Terminal Trun- 
cated (1-320) Murine p53 Is Stimulated by Short Single Strands 
Binding and primer extension footprinting reactions were carried out 
as in Figure 1. 
(Left) Binding reaction mixtures contained 300 ng of murine full-length 
p53 (mp53) (lanes 2-4) and either no DNA fragments (lanes 1 and 2) 
or 500 ng (lane 3) and 1000 ng (lane 4) of short single-stranded DNA 
(ssDNA). Lane 1 contains no protein. 
(Right) Binding reactions contained 400 ng of murine p53(1-320) 
(lanes 2-4) and either no added DNA fragments (lanes 1 and 2) or 
500 ng (lane 3) or 1000 ng (lane 4) of short single-stranded DNA 
(ssDNA). Lane 1 contains no protein. 
central sequence-specific DNA-binding domain with a 
cognate site. Since the interactions of the C-terminus with 
single strands are the result of an independent functional 
domain, it is possible that this region might have an effect 
on the rest of the p53 protein in trans, i.e., as a separate 
entity. We examined whether adding a peptide comprising 
the p53 C-terminus (amino acids 311-393) to full-length 
p53 affects the ability of p53 to bind to DNA. Additionally, 
since the C-terminal 30 amino acids of this region are re- 
quired for the p53 DNA reannealing function, we also 
tested the effects of a C-terminal p53(311-367) peptide 
that lacks this basic region at the end. The purified proteins 
that we used are shown in Figure 3. 
The purified C-terminal p53(311-393) peptide was added 
to full-length p53, and DNA binding to an oligonucleotide 
containing the GADD45 p53 site was examined by the 
electrophoretic mobility shift assay (EMSA). The C-ter- 
minus dramatically stimulated the ability of p53 to bind to 
the GADD45 oligonucleotide (Figure 4A). The magnitude 
of the stimulation, which varied among different experi- 
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Figure 3. Full-Length and Truncated p53 Proteins 
Proteins were analyzed by 10% or 20% SDS-polyacrylamide gel elec- 
trophoresis (SDS-PAGE) and visualized by Coomassie blue staining. 
Abbreviations: h, human; m, routine. 
ments and different preparations of proteins, ranged be- 
tween approximately 10- and 80-fold. The effect was dose 
dependent, reaching a maximum at a ratio of approxi- 
mately 1000 ng of C-termjnus per 100 ng of full-length 
p53 (Figure 4B). The C-terminus peptide also stimulated 
binding of p53 to the GADD45 site in supercoiled DNA 
(unpublished data). Importantly, not o lywas full-length 
p53 Ipinding increased in the presence of the 311-393 
peptide, but the binding by the central core domain, i.e., 
p53 residues 96-312, was also consistently increased, 
although to a somewhat lesser extent, i.e., approximately 
5- to 13-fold (Figure 4C). The murine C-terminus (amino 
acids 315-390) was also capable of stimulating human 
p53 to the same extent as the human p53 C-terminus (com- 
pare lane 1 with lanes 10 and 11 in Figure 4D), and DNA 
binding by full-length murine p53 was also stimulated by 
both the human p53 and muriQe C-terminus peptides (data 
not shown). This leads us to conclude that t e effect of the 
C-terminus on p53 DNA binding is a conserved property of 
p53. A p53 C-terminal peptide that lacks the 30 terminal 
acids (311-367) did not s imulate binding detectably (com- 
pare lane 1 to lanes 6 and 7 in Figure 4D). Thus, the region 
at the distal end of the C-terrain us that contributes to stimu- 
lation of DNA binding is the same as that required for DNA 
reannealing. This suggests that this region of the protein 
is required both for recognition of short single strands and 
regulation of DNA binding by the central sequence-specific 
DNA-binding domain. 
Since the C-terminus itself can bind nonspecifically to 
DNA (Wang et al., 1993), it was important o. ascertain 
whether the increase in DNA binding was specific. To ex- 
amine the specificity of the stimulated DNA binding, we 
employed both a competition EMSA and DNase I foot- 
printing (Figure 5). In each case, it was clear that the in- 
creased binding by p53 was markedly sequence specific. 
By EMSA, all detectable shifted labeled p53 consensus 
site (PCS) DNA was completely competed away by excess 
unlabeled wild-type GADD45 oligonucleotides, while there 
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Figure 4. A Peptide That Spans the C-Ter- 
minus p53(311-393) Stimulates DNA Binding 
by Full-Length p53 
(A) Human p53 (hp53) (50 ng) (lanes 2-4) and 
300 ng (lanes 3 and 5) or 500 ng (lanes 4 and 
6) of human p53(311-393) were incubated with 
a ~P-labeled wild-type GADD45 oligonucleo- 
tide (3 ng) and reaction mixtures analyzed by 
EMSA. Lane 1 contains DNA probe without 
protein. The arrow indicates the p53-DNA 
complex. 
(B) Increasing quantities of p53(311-393) were 
added to p53 (100 ng) in EMSA reaction mix- 
tures containing ~P-labeled wild-type GADD45 
oligonucleotides (3 ng), and after gel elec- 
trophoreses the resulting protein-DNA com- 
plexes were quantitated by phosphorimaging 
using Image-Quant software. 
(C) Human core p53(96-312) (60 ng) (lanes 
1-3) and 300 ng (lane 2) or 500 ng (lane 3) 
of human p53(311-393) were incubated with a 
~P-labeled wild-type GADD45 oligonucleotide 
(3 ng) and reaction mixtures analyzed by 
EMSA. The arrow indicates the p53-DNA 
complex. 
(D) Human p53 (100 ng) (lanes 1-3, 6, 7, 10, 
and 11) was bound to a =P-labeled wild-type 
GADD45 oligonucleotide (3 ng) in the presence 
of 200 ng (lanes 2 and 4) or 400 ng (lanes 3 
and 5) of human p53(311-393); 200 ng (lanes 
6 and 8) or 40~ ng (lanes 7 and 9) of human 
p53(311-367); or 160 ng (lane 10) or 240 ng 
(lane 11) of murine C-terminus p53(315-390) 
peptide as indicated above ach lane. The 
arrow indicates the p53-DNA complex. 
was virtually no competition by similar quantities of mutant 
GADD45 oligonucleotides (Figure 5A). Similarly, in a DNase 
I footprint assay, when an amount of p53 was used that 
only weakly protected the GADD45 site in an end-labeled 
DNA fragment (Figure 5B, lane 1), the protection of this 
region was complete in the presence of the C-terminal 
peptide (lanes 6 and 7). Interestingly, the DNase I hyper- 
cutting induced by p53 (indicated by the arrow in Figure 
5B) was reduced in the presence of p53(311-393). As ex- 
pected, the C-terminal peptide itself showed absolutely no 
protection of this region (Figure 5B, lane 5). 
To confirm further the specificity of the p53 C-terrain us 
for stimulation of p53-specific DNA binding, we asked 
whether unrelated sequence-specific DNA-binding pro- 
teins might be affected in a similar manner by the p53 
C-terminus (Figure 6). We used purified GAL4-VP16 and 
serum response factor (SRF) proteins and tested their 
binding to oligonucleotides containing their cognate sites 
by EMSA. Under all conditions examined, the interaction 
of neither protein with DNA was significantly stimulated 
by the p53 C-terminus peptide. 
Insight into the Mechanism by Which the p53 
C-Terminus Stimulates Specific DNA 
Binding by the Central Core Domain 
The specificity of the effect of the p53 C-terminus on p53 
sequence-specific DNA binding suggested that there 
might be protein-protein interactions between the C-ter- 
minus and the central core of p53. However, we have been 
unable to demonstrate an interaction between the C-ter- 
minal peptide and either full-length p53 or the central 
"core" of p53 (data not shown). Furthermore, there is no 
change in the mobility of p53 protein-DNA complexes in 
the presence of p53(311-393). The C-terminus may thus 
increase specific p53 DNA binding by competing for and 
thereby removing the nonspecific carrier DNA from reac- 
tion mixtures. However, we have three lines of evidence 
against this possibility. First, the fact that the highly se- 
quence-specific central core domain of p53 is strongly 
stimulated by the C-terminus (see~Figure 4C) argues 
against competition for nonspecific DNA. Second, even 
when carrier DNA was absent from the DNA-binding reac- 
tion mixtures, p53(311-393) was highly effective in stimu- 
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Figure 5. TheC-Terminusp53(311-393)Stim- 
ulates Sequence-Specific Binding by Full- 
Length p53 
(A) EMSA competition analysis was performed 
using ~P-labeled p53 consensus site (PCS) oli- 
gonucleotide (3 ng). Reaction mixtures con- 
tained 50 ng of p53 (lanes 1-10) and 300 ng 
of p53(311-393) (lanes 2-10) and either no 
competitor (lanes 1 and 2) or a 13 .3 - ,  50-, 75-, 
and 100-fold excess of unlabeled wild-type (wt) 
GADD45 oligonucleotide (lanes 3-6, respec- 
tively) or a 13.3-, 50-, 75-, and 100-fold excess 
of mutant (mt) GADD45 oligonucleotide com- 
petitor (lanes 7-10, respectively). 
(B) DNase I footprinting was carried out using 
a ~P-labeled wild-type GADD45 DNA fragment 
(0.3 ng) as described in Experimental Proce- 
dures. Reaction mixtures contained no protein 
(lanes 4 and 8), or 250 ng (lanes 1, 6, and 7), 
500 ng (lane 2), or 1000 ng (lane 3) of full-length 
p53 and 1 I~g (lanes 5 and 6) and 2 p.g (lane 
7) of p53(311-393). DNase I hypercutting in- 
duced by p53 is indicated by arrow. 
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lating sequence-speci f ic  DNA binding by p53 (Figure 7). 
Third, results with the p53-specif ic monoclonal  ant ibody 
PAb421, shown previously to st imulate the DNA binding 
properties of p53 (Hupp et al., 1992; Halazonet is  et al., 
1993), argued against  he notion that he C-terminus pep- 
t ide is s imply compet ing for nonspecif ic DNA (Figure 7). 
In this exper iment  we determined the effects of PAb421 
on DNA binding by full-length p53 and by p53(311-393).  
Since no carrier DNA was present, it was possible to detect 
C-terminus-bound DNA (Figure 7A, lane 1, thick arrow). 
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Figure 6. C-Terminus p53(311-393) Does Not 
Significantly Stimulate DNA Binding by SRF or 
GAL4-VP16 Proteins 
EMSAs were performed with 32P-labeled oligo- 
nucleotides (3 ng) containing either wild-type 
GADD45-, SRF-, or GAL4-binding sites. Arrows 
indicate pqsitions of specific protein-DNA 
complexes. 
(Left) Reaction mixtures contained p53 (100 
ng; lanes 1-3) and either 300 ng (lanes 2 and 
4) or 500 ng (lanes 3 and 5) of C-terminus 
p53(311-393) peptide. 
(Middle) Reaction mixtures contained SRF (30 
ng; lanes 1-4) and either 100 ng (lanes 2 and 
5), 300 ng (lanes 3 and 6), or 500 ng (lanes 4 
and 7) of p53(311-393). 
(Bottom) Reaction mixtures contained 200 ng 
(lanes 2 and 4) or 400 ng (lanes 3 and 6) of 
p53 C-terminus peptide and either 4 ng (lanes 
1-3) or 8 ng (lanes 4-6) of SRF. 
(Right) Reaction mixtures contained 20 ng of 
GAL4-VP16 (lanes 1-3) and 300 ng (lanes 2 
and 4) or 500 ng (lanes 3 and 5) of C-terminus 
p53(311-393) peptide. 
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Figure 7. C-Terminus p53(311-393) Stimulates DNA Binding by p53 
in the Presence of Monoclonal Antibody PAb421 
(A) EMSA was performed after p53 (50 ng) was bound to a 32P-labeled 
p53 consensus site oligonucleotide (3ng) as described in Experimental 
Procedures. However, reaction mixtures contained no poly(dl-dC). 
Where indicated above lanes, 300 ng of C-terminus p53(311-393) 
peptide was added; 2 p.I (lanes 3, 7, and 10), 3 I~1 (lanes 4, 8, and 11), 
or 4 pJ (lanes 5, 9, and 12) of p53-specific monoclonal antibody PAb421 
were added as indicated. 
(B) Graphic representation of protein-DNA complexes (all forms) 
shown in (A) quantitated by phosphorimaging. Thick arrow indicates 
C-terminus-bound DNA; long arrow indicates PAb421-shifted p53- 
DNA complex; short arrow indicates the p53 complex that is stimulated 
by the C-terminal peptide (311-393). 
Additional!y, we measured binding by p53 in the presence 
of both PAb421 (long arrow in Figure 7A) and the C-ter- 
minal peptide (short arrow in Figure 7A). As shown pre- 
viously, PAb421 stimulated and shifted the p53-DNA com- 
plex (Figure 7A, lanes 3-5). However, under conditions 
that allowed detection of the binding of the oligonucleotide 
by p53(311-393) (see Figure 7A, lane 1), PAb421 inhibited 
such binding (compare lanes 1 and 10-12). In the pres- 
ence of both full-length p53 and p53(311-393), increasing 
levels of PAb421 led to increased binding over what was 
seen with PAb421 alone (compare lanes 5 and 9 in Figure 
7A). Therefore, PAb421, while inhibiting DNA binding by 
p53(311-393), did not block its ability to stimulate full- 
length p53 DNA binding. By contrast, at lower concentra- 
tions of PAb421, the C-terminus apparently reduced the 
extent to which PAb421 shifted the p53-DNA complex 
in the EMSA. Taken together, our data suggest that 
p53(311-393) transiently (but undetectably) interacts with 
full-length p53, leading to augmentation of its ability to 
bind specifically to its cognate sites. 
Discussion 
It is likely that there are at least two ways in which p53 
is up-regulated after DNA damage. That p53 °levels are 
increased and stabilized after treatment of cells with 
agents that induce DNA damage has been well docu- 
mented. Additionally, it is reasonable to assume that p53 
in cells is intrinsically more active for DNA binding and 
transcriptional activity after DNA damage. This latter pos- 
sibility is supported by the following p53 features. First, 
p53 can exist in at least two conformations that differ in 
their ability to interact with DNA (Hupp and Lane, 1994; 
Halazonetis and Kandil, 1993). Furthermore, the C-ter- 
minus of p53 contains a determinant hat is responsible 
for these alternate conformations. Indeed, the region of 
the C-terminus that is most likely to be regulatory, i.e., the 
last 30 amino acids, is also the region that we have shown 
is necessary for the stimulation of p53 by the C-terminal 
peptide. The likely possibility that p53 exists in latent and 
active forms implies that there are effectors in cells that 
can bring about a shift between these two forms. Second, 
the C-terminus of p53 displays properties that suggest that 
it can interact in a unique way with short single-stranded 
nucleic acids. Extending previous studies showing that 
full-length p53 can reanneal complementary DNA and 
RNA single strands, several groups have now shown that 
the p53 C-terminus is solely responsible for this activity. 
Third, Bakalkin et al. (1994), using electron microscopy, 
have shown that p53 binds directlyIo the ends of single- 
stranded DNA. Possibly the most attractive speculation 
emerging from our data is that p53 recognizes DNA struc- 
tures in cells akin to those that stimulate binding in vitro 
and that such recognition alters it such that it is converted 
from a form that is inactive for DNA binding to one that 
is active. This would establish a direct link between DNA 
damage and the property of p53 that is most likely to be 
required for its function as a tumor suppressor, namely, 
sequence-specific DNA binding. 
How does the C-terminal peptide stimulate binding in 
trans? There may be more than one component o its stim- 
ulatory effects. It is possible to suggest a model in which 
some other region of p53, perhaps at the N-terminus, con- 
tains a negative regulatory sequence that is held in this 
repressive conformation through an interaction with the 
C-terminus. Interaction with effectors such as single- 
stranded DNA would alter the C-terr~inus such that it 
would release the N-terminus and thus make available the 
central region for binding with DNA. Adding the C-terminus 
in trans might similarly titrate the N-terminus away from 
its negative regulatory conformation. However, since the 
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C-terminus of p53 is capable of stimulating, albeit to a 
lesser extent, the ability of the central site-specific p53 
core to bind to DNA, there is clearly a direct effect of the 
C-terminus on the DNA-binding domain. The most reason- 
able view of all this, notwithstanding,, is that full under- 
standing of the roles of the C-terminus is not yet available 
and that, however it acts, the C-terminal 30 amino acids 
are clearly an important regulatory part of~the protein. 
In our initial experiments, we used EMSAto test the 
effects of long or short single- or double-stranded DNA on 
p53 sequence-specific binding to a labeled GADD45 site 
duplex oligomer. Our results showed that while short sin- 
gle strands had no effect, all other forms of DNA reduced 
sequence-specific binding (unpublished ata). One expla- 
nation for our inability to detect a stimulatory effect by 
EMSA is that the short labeled oligomers characteristically 
used in this assay consist almost entirely of the p53 site, 
while with a supercoiled plasmid, p53 would have to "seek 
and find" its site over a considerable distance of DNA. It 
is therefore possible that short single-stranded oligonu- 
cleotides timulate binding by increasing the relative affin- 
ity of p53 for a specific site in nonspecific ontiguous DNA 
or, more speculatively, by facilitation of movement along 
DNA to find a binding site. 
It is remarkable that only short oligonucleotides were 
effective in stimulating p53 sequence-specific binding. Al- 
though we do not know the precise length of the shortest 
stimulatory oligonucleotide, we have found that one con- 
taining only 16 nucleotides is also capable of activating 
DNA binding (data not shown). However, at the upper limit, 
an oligonucleotide with as few as 66 nucleotides was inhib- 
itory to p53 sequence-specific binding. This is consistent 
with results of Bakalkin et al. (1995), who have evidence 
suggesting that two discrete domains of p53 interact with 
single-stranded DNA: the C-terminus, which recognizes 
short oligonucleotides, and the central domain, which 
binds to long single strands. Since we found that the 66- 
met is inhibitory to site-specific binding, this would imply 
that this oligonucleotide is of sufficient length to bind pref- 
erentially to the central region of p53 and to Prevent its 
binding to a cognate site. By contrast, oligomers ranging 
between 16 and 40 nucleotides bind the C-terminus of 
p53, and this facilitates the interaction of the central do- 
main with p53 response elements. Whether or not the 
short single-stranded oligomers remain associated with 
the p53 C-terminus when the protein is bound to its site 
in double-stranded DNA is currently under investigation. 
One consideration in the interpretation of our data is the 
improbability hat within cells subjected to DNA-damaging 
agents DNA lesions would occur within the vicinity of a 
p53-responsive gene. Clearly, therefore, a brief transient 
effect of single-stranded DNA on p53 would not be relevant 
to the cellular p53 DNA damage response. However, if 
the effect of single strands on existing p53 molecules in 
cells were to be of significant duration or even irreversible, 
then it is possible to envision a more long-range propaga- 
tion of the effect of DNA damage on p53. The fact that 
purified p53 associates and dissociates from DNA rapidly 
(Bargonetti et al., 1992) suggests that mechanisms may 
exist in cells for stabilizing its binding. 
How would p53 find short single strands resulting from 
DNA damage in cells? Indeed, there are aspects of the 
DNA repair process that might well intersect with p53. p53 
itself has the ability to recognize and bind to some forms 
of DNA lesions, such as certain mismatches (Lee et al., 
1995 [this issue of Cell]) or single strand ends. Different 
components of the excision repair complex have been re- 
ported to interact with p53. The single-stranded binding 
protein RPA has been shown to associate with the activa- 
tion domains of p53 and VP16 and possibly other activa- 
tors as well (Dutta et al., 1993; He et al., 1993; Li and 
Botchan, 1993). Additionally, the basal transcription factor 
TFIIH (Xiao et al., 1994) and the ERCC3 polypeptide com- 
ponent of TFIIH (Wang et al., 1994) have'been reported 
to bind p53. Human excision repair is carried out by a 
large complex of polypeptides that includes both RPA and 
TFIIH (reviewed by Sancar, 1994). The human excinucle- 
ase complex first recognizes ultraviolet-damaged DNA 
and then introduces ingle strand incisions at positions 3' 
and 5' to the mismatch (Huang et al., 1992). A product of 
the subsequent repair of the lesion is the release of a 
single-stranded 29-mer. This short oligonucleotide is then 
an excellent candidate for a physiologically relevant acti- 
vator of p53 DNA binding. It is tempting to speculate that 
the interaction of p53 either with proteins such as RPA or 
TFIIH or with DNA lesions directly may result in its recruit- 
ment to the site of damaged DNA so that it can be activated 
by the oligonucleotide product of the excision repair re- 
action. 
Experimental Procedures 
Purification of p53 Proteins 
Sf-21 cells were infected with human p53 recombinant virus, harvested 
48 hr postinfection, and extracted, and full-length p53 protein was 
immunopurified ssentially as described by Friedman et al. (1990). 
Baculoviruses expressing His-tagged murine full-length p53 or trun- 
cated murine p53(1-320) and p53(315-320) proteins were provided by 
P. Tegtmeyer. Human central core p53(96-312) and human p53(311- 
393) and p53(311-367) C-terminus peptides were a gift from N. Pavleo 
tich and were prepared as described'by Pavletich et al. (1993). SRF 
(Manak et al., 1990) and GAL4-VP16 (Zhu et al., 1994) proteins were 
provided by members of the R. Prywes laboratory. 
EMSAs 
EMSA was carried out as described previously (Chen et al., 1993). 
Sequences of the oligonucleotide probes containing either wild-type 
or mutant p53 consensus equence are as follows: GADD45 wild 
type, AATI'CTCGAGCAGAACATGTCTAAGCATGCTGGGCTCGAG; 
GADD45 mutant, AATTCTCGAGCAGAAAATTTCTAAGAATrCTGG- 
GCTCGAG; p53 consensus ite (PCS) wild type, TCGAGAGACA- 
TGCCCAGGCATGCCTC. The oligonucleotides containing the SRF- 
binding site (CAATCCCTCCCCCCTTATGAAAGATGCCCATATATG- 
GGCATCTTCTGCAGCA) (Manak et al., 1990) and the GAL4-VP16- 
binding site (TCGAGCGGAGGACT/^GTCCTC) (Johansen and 
Prywes, 1993) were gifts from R. Prywes and coworkers. Probes were 
labeled by the Klenow fragment of Escherichia coil DNA polymerase. 
Reaction mixtures contained 8 p~l of 5 x EMSA buffer (i00 rnM HEPES 
[pH 7.9], 125 mM KCI, 0.5 rnM EDTA, 50% glycerol, 10 mM MgCI), 
2 p.I of 40 mM spermidine, 2 I~1 of 10 mM DTT, 2 p~l of 0.5% NP-40, 
2 p.I of 60 p.g/ml double-stranded poly(dl-dC), 4 p.I of bovine serum 
albumin (BSA) (1 mg/rnl), uP-labeled probe DNA (3 ng), proteins as 
indicated, and water in a total volume of 40 p.I. Reaction mixtures were 
incubated at room temperature for 40 min; 20 p.I of each reac- 
tion mixture was then loaded onto a native 4% po!yacrylamide g l 
containing 0.Sx Tris-borate-EDTA (TBE) buffer, 1 mM EDTA, and 
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0.05% NP-40 and electrophoresed in 0.5x TBE at 4°C at 200-250 
V for 2 hr. 
DNase I Footprinting Assays 
Analysis of p53 bound to supercoiled DNA was carried out as described 
previously (Gralla, 1985). Reaction mixtures contained 10 pLI of 5 X 
footprint buffer (31 mM MgCI, 163 m M HEPES [pH 7.9], 2.5 mM DTT, 
250 mM KCI, 500 I~g/ml BSA, 0.25 mM EDTA, 25% glycerol, 0.125% 
NP-40, and 2.5 mM spermidine), 20 p.I of water, 1 p.I of plasmid DNA 
(100 ng/p,I), buffer BC100 (20 mM Tris [pH 8.0], 20% glycerol, 0.1 M 
KCI, 0.2 mM EDTA), p53 proteins, and DNA as indicated in a final 
volume of 50 p,L The plasmid DNA used was pBluescript containing 
the GADD45 site (see above) cloned into the EcoRI site. The bottom 
strand of the GADD45 mutant oligonucleotide (described earlier) was 
used for short single-stranded DNA, and the hybridized double- 
stranded mutant GADD45 oligonucleotide was used for short double- 
stranded DNA in Figure 1A. pUC19 plasmid DNA cut at the unique 
EcoRI site was used for long double-stranded DNA. Long single- 
stranded DNA was prepared by heating the EcoRI-cut pUC19 plasmid 
DNA at 92°C for 5 min and then adding it directly to the binding mixture 
on ice. Sequences of oligonucleotides used in the Figure 1B were as 
follows: 19-mar, CGCCCACGGATCTGAAGGG; 21-mar, CATGAGC- 
GCTGCTCAGATAGC; 30-mar, CCAGCTGCAGCTCCACTGGATG- 
GAGAATAT; 66-mer, GATCGAA'I-rCACCATGGGCTACCCATAC- 
GATGTI'CCAGATTACGCTGAGGAGCCGCAGTCAGATCC; 92-mar, 
AGTAGTGTAGGAATTC-N60-CTCGAGAGGTCACAGT (N is any nu- 
cleotide). Reaction mixtures were incubated on ice for 30 min followed 
by DNase I digestion. The amount of DNase I used was pretested 
empirically to produce an even pattern of partial cleavage products. 
DNase I reactions were performed on ice for 2 rnin and stopped by 
adding 20 p.I of DNase I stop buffer (1% SDS, 20 mM EDTA, 200 mM 
KCI, and 250 p.g/ml yeast tRNA). The DNAs were extracted with phenol 
and heated at 80°C for 2 rain, and the aqueous phase was loaded on 
a prespun G-50 Sephadex column and centrifuged at 2300 rpm for 5 
min. The eluate was collected and the volume made up to 70 p.I with 
water.. 
Primer extension of the DNase I-digasted fragments was done us- 
ing the 20-mer SK primer (Stratagene). The primer was =P labeled 
with T4 polynucleotide kinase and [7-=P]ATP. To half the DNase 
I-treated samples, 1 p,I of primer and 4 p,I of 50 mM NaOH were added, 
and then the mixture was heated at 80°C for 3 min to denature the 
DNA. The samples were fast-cooled on ice, and 10 p.I of primer exten- 
sion buffer (500 mM Tris [pH 7.2], 100 mM Mg2SO,, and 2 mM D'l-r) 
was added and incubated at 45°C for 3 min for annealing. A dNTP 
mixture (2.5 mM of each NTP; 40 Id total) was added to each of the 
samples and the volume made up to 100 p.I with water. Extension 
reactions were then performed with the Klenow fragment of E. coil 
DNA polymerase at 52°C for 10 min. Reactions were stopped with 25 
~1 of stop mix (4 M sodium acetate and 20 mM EDTA), and the DNA 
was ethanol precipitated and resuspended in deionized formamide. 
The DNA fragments were electrophorased on a gel of 8% polyacryl- 
amide and 7 M urea. 
DNase I footprinting of p53 bound to a linear =P-labeled 120 bp 
DNA fragment from the pBluascript plasmid containing the wild-type 
GADD45 site was performed as described previously (Chenet al., 
1993). 
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